{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:59:08Z","timestamp":1789178348473,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with major depressive disorder (MDD), achieving remission and\/or response may take many months because of the lengthy trial-and-error process often needed to identify effective medication. Pharmacogenomic testing is a prescribing tool that has been shown to improve remission and response rates for MDD patients, but data describing its impact over time is limited. The objective of this study was to determine whether pharmacogenomic-guided treatment increases the rate of remission and response over time in patients with MDD, and if so, to assess the persistence of that effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study was a prespecified\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis of the PRIME Care (Precision Medicine in Mental Healthcare) randomized clinical trial, a pragmatic trial that compared pharmacogenomic-guided treatment with usual care among veterans with depression. Participants were recruited at 22 Department of Veterans Affairs medical centers by 676 clinicians and were randomized to the pharmacogenomic-guided arm or the usual care arm. Multivariate Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between study arm (pharmacogenomic-guided treatment or usual care) and the first instance of response or remission as assessed by the Patient Health Questionnaire-9 (PHQ-9) scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1,764 (90.7%) of the 1,944 veterans who participated in the PRIME Care trial had sufficient visit data to be included in this analysis. Patients who received pharmacogenomic-guided treatment had higher rates of remission (HR [95% CI] = 1.27 [1.05, 1.53]; p = 0.015) and response (HR [95% CI] = 1.21 [1.05, 1.40]; p = 0.010) at any time relative to patients receiving usual care. Schoenfeld residuals tests were not statistically significant for remission (p = 0.931) or response (p = 0.112), providing no evidence that the benefit due to pharmacogenomic-guided treatment changed over the 24-week period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacogenomic-guided treatment led to faster initial remission and response in patients with MDD, and this benefit persisted over 6\u00a0months with no evidence of changing over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1658616","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:23:52Z","timestamp":1761805432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder"],"prefix":"10.3389","volume":"16","author":[{"given":"Daniel","family":"Hain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andria L.","family":"Del Tredici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Mabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Johansen Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Oslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000002061","article-title":"Meta-analysis of response and remission outcomes with a weighted multi-gene pharmacogenomic test for adults with depression","author":"Albers","year":"2025","journal-title":"J. Clin. Psychopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2022.12.147","article-title":"The impact of early remission on disease trajectory and patient outcomes in major depression disorder (MDD): a targeted literature review and microsimulation modeling approach based on the sequenced treatment alternatives to relieve depression (STAR*D) study","volume":"325","author":"Arnaud","year":"2023","journal-title":"J. Affect Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104965","DOI":"10.1016\/j.neubiorev.2022.104965","article-title":"Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: systematic review and meta-analysis of randomised controlled trials","volume":"144","author":"Arnone","year":"2023","journal-title":"Neurosci. Biobehav Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41431-024-01648-1","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and Non-SSRI\/Non-TCA antidepressants","volume":"32","author":"Beunk","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1017\/S0033291723002817","article-title":"The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review","volume":"53","author":"Bousman","year":"","journal-title":"Psychol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta\u2010analysis of prospective, controlled clinical trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"115102","DOI":"10.1016\/j.psychres.2023.115102","article-title":"Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis","volume":"321","author":"Bunka","year":"2023","journal-title":"Psychiatry Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4088\/JCP.10m06314","article-title":"Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study","volume":"73","author":"Ciudad","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/JCP.0000000000001999","article-title":"Real-world impact of pharmacogenomic testing on medication use and healthcare resource utilization in patients with major depressive disorder","volume":"45","author":"Del Tredici","year":"2025","journal-title":"J. Clin. Psychopharmacol."},{"key":"B11","unstructured":"FDA table of pharmacogenetic associations\n          \n          \n          2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/21556660.2019.1612410","article-title":"Economic burden of relapse\/recurrence in patients with major depressive disorder","volume":"8","author":"Gauthier","year":"2019","journal-title":"J. Drug Assess."},{"key":"B13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0140-6736(03)12599-8","article-title":"Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review","volume":"361","author":"Geddes","year":"2003","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.4088\/JCP.9078tx1c","article-title":"A review of the current guidelines for depression treatment","volume":"71","author":"Gelenberg","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, Patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1007\/s12325-023-02622-x","article-title":"The economic burden of adults with major depressive disorder in the United States (2019)","volume":"40","author":"Greenberg","year":"2023","journal-title":"Adv. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","article-title":"Pharmacological approaches to the challenge of treatment-resistant depression","volume":"17","author":"Ionescu","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12888-019-2418-7","article-title":"Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019","volume":"20","author":"Kern","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1007\/b97377","volume-title":"Survival analysis: techniques for censored and truncated data","author":"Klein","year":"2003"},{"key":"B22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jad.2022.09.162","article-title":"Predicting relapse from the time to remission during the acute treatment of depression: a Re-Analysis of the STAR*D data","volume":"320","author":"Kubo","year":"2023","journal-title":"J. Affect Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: r\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023: mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"Lam","year":"2023","journal-title":"Can. J. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0238843","DOI":"10.1371\/journal.pone.0238843","article-title":"A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.7326\/M22-1603","article-title":"The management of major depressive disorder: synopsis of the 2022 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline","volume":"175","author":"McQuaid","year":"2022","journal-title":"ACP J. Club"},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","article-title":"Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"81","author":"Milosavljevi\u0107","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0197268","DOI":"10.1371\/journal.pone.0197268","article-title":"Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study","volume":"13","author":"Nie","year":"2018","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"106247","DOI":"10.1016\/j.cct.2020.106247","article-title":"Study design and implementation of the PRecision medicine in MEntal health care (PRIME care) trial","volume":"101","author":"Oslin","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"B29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"key":"B30","unstructured":"R: a language and environment for statistical computing\n          \n          \n          2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jad.2011.05.051","article-title":"Clinical differences between early and late remission in depressive patients","volume":"134","author":"Roca","year":"2011","journal-title":"J. Affect Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jad.2024.09.041","article-title":"Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: a systematic review and meta-analysis","volume":"367","author":"Santenna","year":"2024","journal-title":"J. Affect Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41386-023-01647-8","article-title":"The why, when, where, how, and so what of so-called rapidly acting antidepressants","volume":"49","author":"Schatzberg","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"B35","unstructured":"Patient health Questionnaire-9 (PHQ-9)\n          \n          \n            \n              Spitzer\n              R. L.\n            \n            \n              Williams\n              J. B. W.\n            \n            \n              Kroenke\n              K.\n            \n          \n          \n          1999"},{"key":"B36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12888-022-03793-7","article-title":"Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data","volume":"22","author":"Touya","year":"2022","journal-title":"BMC Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.31887\/DCNS.2008.10.4\/mhtrivedi","article-title":"Treatment strategies to improve and sustain remission in major depressive disorder","volume":"10","author":"Trivedi","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2312443","DOI":"10.1001\/jamanetworkopen.2023.12443","article-title":"Effectiveness of genotype-specific tricyclic antidepressant dosing in patients with major depressive disorder","volume":"6","author":"Vos","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12888-023-04756-2","article-title":"Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B40","unstructured":"The PTSD checklist for DSM-5 (PCL-5)\n          \n          \n            \n              Weathers\n              F. W.\n            \n            \n              Litz\n              B. T.\n            \n            \n              Keane\n              T. M.\n            \n            \n              Palmieri\n              P. A.\n            \n            \n              Marx\n              B. P.\n            \n            \n              Schnurr\n              P. P.\n            \n          \n          \n          2013"},{"key":"B41","unstructured":"Depressive disorders (depression)\n          \n          \n          2023"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1658616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:23:54Z","timestamp":1761805434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1658616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":41,"alternative-id":["10.3389\/fphar.2025.1658616"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1658616","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"1658616"}}